ES8802329A1 - Un procedimiento para preparar un polipetido que tiene en parte o en su totalidad la conformacion estructural primaria de la critropoyetina de origen natural. - Google Patents

Un procedimiento para preparar un polipetido que tiene en parte o en su totalidad la conformacion estructural primaria de la critropoyetina de origen natural.

Info

Publication number
ES8802329A1
ES8802329A1 ES538519A ES538519A ES8802329A1 ES 8802329 A1 ES8802329 A1 ES 8802329A1 ES 538519 A ES538519 A ES 538519A ES 538519 A ES538519 A ES 538519A ES 8802329 A1 ES8802329 A1 ES 8802329A1
Authority
ES
Spain
Prior art keywords
epo
disclosed
dna
cdna
procaryotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES538519A
Other languages
English (en)
Spanish (es)
Other versions
ES538519A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen K A Inc
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27504819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8802329(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/675,298 external-priority patent/US4703008A/en
Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc
Publication of ES8802329A1 publication Critical patent/ES8802329A1/es
Publication of ES538519A0 publication Critical patent/ES538519A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES538519A 1983-12-13 1984-12-12 Un procedimiento para preparar un polipetido que tiene en parte o en su totalidad la conformacion estructural primaria de la critropoyetina de origen natural. Expired ES8802329A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56102483A 1983-12-13 1983-12-13
US58218584A 1984-02-21 1984-02-21
US65584184A 1984-09-28 1984-09-28
US06/675,298 US4703008A (en) 1983-12-13 1984-11-30 DNA sequences encoding erythropoietin

Publications (2)

Publication Number Publication Date
ES8802329A1 true ES8802329A1 (es) 1988-05-01
ES538519A0 ES538519A0 (es) 1988-05-01

Family

ID=27504819

Family Applications (1)

Application Number Title Priority Date Filing Date
ES538519A Expired ES8802329A1 (es) 1983-12-13 1984-12-12 Un procedimiento para preparar un polipetido que tiene en parte o en su totalidad la conformacion estructural primaria de la critropoyetina de origen natural.

Country Status (15)

Country Link
US (3) US5441868A (enExample)
EP (1) EP0148605B2 (enExample)
JP (9) JPH0655136B2 (enExample)
AU (5) AU5750490A (enExample)
CA (1) CA1339047C (enExample)
CY (1) CY1643A (enExample)
DE (1) DE3482828D1 (enExample)
ES (1) ES8802329A1 (enExample)
HK (1) HK20093A (enExample)
IL (1) IL73785A (enExample)
MX (1) MX9203598A (enExample)
NL (1) NL930128I1 (enExample)
NZ (1) NZ210501A (enExample)
SG (1) SG92891G (enExample)
WO (1) WO1985002610A1 (enExample)

Families Citing this family (359)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72786B (en) 1980-04-03 1983-01-10 Biogen Nv Process for producing dna sequences recombinant dna molecules and human fibroplast interferon-like polypeptides
IT1185503B (it) * 1984-01-11 1987-11-12 Univ New York Cloni di odna di eritropietina umana
IL77081A (en) * 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
JPS62501010A (ja) 1984-12-04 1987-04-23 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド エリトロポエチンの生産方法
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4732889A (en) * 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
GB2177914B (en) * 1985-06-04 1989-10-25 Chugai Pharmaceutical Co Ltd A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
IL79176A (en) * 1985-06-20 1992-06-21 Kirin Amgen Inc Process for the recovery of erythropoietin from a fluid
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
US4935350A (en) * 1985-11-18 1990-06-19 Amgen Materials and methods for controlling plasmid copy number and stability
JPS62171696A (ja) * 1986-01-23 1987-07-28 Sumitomo Chem Co Ltd ヒトエリスロポエチンの製造方法
EP0236059B1 (en) * 1986-02-27 1994-04-27 Snow Brand Milk Products Co. Ltd. Preparation of erythropoietin-producing cells and production process of erythropoietin using same
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
GR871029B (en) 1986-07-14 1987-11-02 Genetics Inst Novel osteoinductive factors
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
WO1988005466A2 (en) * 1987-01-15 1988-07-28 Codon Tandem gene eukaryotic expression vectors
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
JP2791418B2 (ja) 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えｄｎａ、形質転換体
DE3923963A1 (de) * 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
US6932968B1 (en) 1989-07-26 2005-08-23 Dade Behring Marburg Gmbh Erythropoietin (EPO) peptides and antibodies directed against these
KR100263845B1 (ko) * 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
DE4115722A1 (de) * 1991-05-14 1992-11-19 Boehringer Mannheim Gmbh Serumfreies medium zur kultivierung von saeugerzellen
US5968502A (en) * 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5728536A (en) * 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
WO1994005679A1 (fr) * 1992-09-09 1994-03-17 Nippon Kayaku Kabushiki Kaisha Nouvelle substance physiologiquement active appelee nk175203, son procede de production et son utilisation pharmaceutique
WO1994024160A2 (en) * 1993-04-21 1994-10-27 Brigham And Women's Hospital Erythropoietin muteins with enhanced activity
IL192290A0 (en) * 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
US8192955B1 (en) * 1994-01-03 2012-06-05 Genentech, Inc. Nucleic acids encoding MPL ligand (thrombopoietin), variants, and fragments thereof
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
IL118201A (en) * 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
KR100459984B1 (ko) * 1995-06-07 2005-06-20 아피맥스 테크놀로지스, 엔.브이. 에리트로포이에틴수용체(epo-r)에결합하는화합물및펩티드
EP0833934B2 (en) 1995-06-15 2012-08-15 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
EP0752474A1 (en) * 1995-07-07 1997-01-08 Boehringer Mannheim Gmbh Nucleic acid coding for CMP-N-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
WO1997003200A1 (en) * 1995-07-07 1997-01-30 Boehringer Mannheim Gmbh Nucleic acid coding for cmp-n-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
KR970010968A (ko) * 1995-08-24 1997-03-27 윤원영 오리 배 세포를 이용한 에리스로포이틴의 발현 시스템
ES2206695T3 (es) 1996-03-14 2004-05-16 Genentech, Inc. Receptor de gdnf y utiolizacion del mismo.
GB2318352A (en) * 1996-06-25 1998-04-22 Dejan Markovic Polypeptides mimicking the activity of human erythropoietin
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
AU753701B2 (en) * 1997-04-21 2002-10-24 Glycozyme, Inc. Determination of recombinant glycosylated proteins and peptides in biological fluids
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6187564B1 (en) * 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
DE19729769A1 (de) 1997-07-11 1999-01-14 Cardiogene Gentherapeutische S Transfektionssystem, seine Herstellung und Verwendung in der somatischen Gentherapie
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6740503B1 (en) 1997-09-26 2004-05-25 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US6897066B1 (en) * 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
PT1023442E (pt) * 1997-10-16 2011-02-25 Synageva Biopharma Corp Vectores compreendendo um promotor específico do magno para transgénese aviária
CA2693296C (en) * 1997-12-08 2013-09-10 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
RU2125093C1 (ru) * 1998-02-12 1999-01-20 Государственный научно-исследовательский институт особо чистых биопрепаратов Способ получения рекомбинантного человеческого эритропоэтина, штамм культивируемых клеток яичника китайского хомяка - продуцент эритропоэтина
US7037663B2 (en) * 1998-02-19 2006-05-02 Eastern Virginia Medical School Human zona pellucida protein 3 and uses thereof
EP1056858B1 (en) * 1998-02-19 2004-12-08 Eastern Virginia Medical School RECOMBINANT ACTIVE HUMAN ZONA PELLUCIDA PROTEIN 3 (hZP3)
ES2224299T3 (es) 1998-02-23 2005-03-01 Cilag Ag International Dispersion liposomal de eritroyetina.
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
KR100434729B1 (ko) * 1998-03-18 2004-11-03 주식회사 엘지생명과학 천연 추출물을 첨가하여 중국햄스터 난소 유래세포에서 에리스로포이에틴의 생산 증대방법
JP2002509729A (ja) * 1998-03-27 2002-04-02 サイトス バイオテクノロジー アーゲー 誘導性のアルファウイルス遺伝子発現系
AR019025A1 (es) 1998-04-09 2001-12-26 Roche Diagnostics Gmbh Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
MXPA00010070A (es) * 1998-04-15 2004-03-10 Lexigen Pharm Corp Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis.
US6696411B1 (en) * 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
EP1071795A4 (en) 1998-04-22 2005-01-19 Cornell Res Foundation Inc CANINE ERITHROPOIETINE GENE AND RECOMBINANT PROTEIN
WO1999066054A2 (en) 1998-06-15 1999-12-23 Genzyme Transgenics Corp. Erythropoietin analog-human serum albumin fusion protein
US20050181482A1 (en) * 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
EP1100545A4 (en) * 1998-07-29 2002-03-20 Invitrogen Corp REGULATED EXPRESSION OF RECOMBINANT PROTEINS USING RNA VIRUSES
EP0984062A1 (en) * 1998-09-04 2000-03-08 Cytos Biotechnology AG Production of human erythropoietin
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
BR9917606A (pt) 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
BR9905867A (pt) * 1998-11-06 2001-01-23 Bio Sidus S A Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
BR9905868A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7604960B2 (en) * 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US8236561B2 (en) * 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
AU766507B2 (en) * 1999-05-07 2003-10-16 Genentech Inc. Novel chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6555343B1 (en) 1999-05-07 2003-04-29 Genentech Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6831060B2 (en) 1999-05-07 2004-12-14 Genentech, Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6737519B1 (en) * 1999-07-30 2004-05-18 Genome Therapeutics Corporation Human genes relating to respiratory diseases and obesity
HUP0202442A3 (en) * 1999-08-09 2005-01-28 Lexigen Pharmaceuticals Corp L Multiple cytokine-antibody complexes
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
AU2154401A (en) 1999-11-12 2001-05-30 Merck Patent Gmbh Erythropoietin forms with improved properties
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
WO2001042442A2 (en) 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation of endogenous genes by genomic introduction of a replicon
DK1252192T3 (da) * 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSED PROTEINS
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
IES20010462A2 (en) * 2000-05-12 2001-11-14 Cyril John Higgins Use of the world wide web
DK1294401T3 (da) * 2000-06-29 2007-10-08 Merck Patent Gmbh Forbedring af antistof/cytokin-fusionsproteinmedierede immunresponser ved kombineret behandling med immuncytokin-optagelsesforberende midler
US20020012982A1 (en) * 2000-07-13 2002-01-31 Invitrogen Corporation Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
ATE428790T1 (de) 2000-09-25 2009-05-15 Genetronics Inc Verbessertes system zur regulation der transgenexpression
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
KR100645843B1 (ko) 2000-12-20 2006-11-14 에프. 호프만-라 로슈 아게 에리트로포이에틴 접합체
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
KR100399337B1 (ko) * 2001-02-07 2003-09-26 드림바이오젠 주식회사 단백질의 무세포 번역후수식법
MXPA03008031A (es) 2001-03-07 2003-12-04 Merck Patent Gmbh Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CN100503639C (zh) 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
AU2002310122A1 (en) * 2001-05-25 2002-12-09 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US7148021B2 (en) * 2001-08-02 2006-12-12 Eastern Virginia Meical School Human zona pellucida proteins and methods of their use in diagnosing male infertility
WO2003018782A2 (en) * 2001-08-30 2003-03-06 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US7393830B2 (en) * 2001-09-14 2008-07-01 Stem Cell Therapeutics Inc. Prolactin induced increase in neural stem cell numbers
EP1430113A2 (en) * 2001-09-18 2004-06-23 Stem Cell Therapeutics Inc. Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
PL368749A1 (en) * 2001-11-28 2005-04-04 Sandoz Ag Cell culture process
BR0214650A (pt) * 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
ATE384785T1 (de) * 2001-12-07 2008-02-15 Crucell Holland Bv Herstellung von viren, virusisolaten, und impfstoffen
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2003059934A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003226960B2 (en) 2002-01-17 2007-11-22 Lonza Biologics Plc. Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CA2485365A1 (en) * 2002-05-13 2003-11-20 Modigenetech Ltd. Ctp-extended erythropoietin
EA010200B1 (ru) * 2002-07-01 2008-06-30 Дзе Кеннет С. Уоррен Инститьют, Инк. Рекомбинантные тканезащитные цитокины и кодирующие их нуклеиновые кислоты для защиты, восстановления и усиления чувствительных клеток, тканей и органов
EP2287288B1 (en) 2002-07-09 2012-11-07 Baxter International Inc. Animal protein free media for cultivation of cells
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
CA2492442A1 (en) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
KR100521309B1 (ko) * 2002-08-31 2005-10-14 씨제이 주식회사 당쇄화된 인간 과립구 형성인자
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
DE20321793U1 (de) 2002-09-11 2010-06-02 Fresenius Kabi Deutschland Gmbh Hydroxyalkylstärke-Derivate
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
PL217085B1 (pl) 2002-09-11 2014-06-30 Fresenius Kabi Gmbh Koniugat hydroksyalkiloskrobi i polipeptydu, sposób wytwarzania koniugatu hydroksyalkiloskrobi i polipeptydu, zastosowanie koniugatu hydroksyalkiloskrobi i polipeptydu oraz kompozycja farmaceutyczna koniugatu hydroksyalkiloskrobi i polipeptydu
EP1549350B1 (en) 2002-10-08 2008-09-24 Fresenius Kabi Deutschland GmbH Pharmaceutically active oligosaccharide conjugates
EP1572748B1 (en) * 2002-12-17 2010-06-23 MERCK PATENT GmbH Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
ZA200506196B (en) * 2003-02-03 2006-10-25 Japan Immuno Inc High-expression vector for animal cells
EP1624883A4 (en) * 2003-04-09 2008-11-26 Univ Utah Res Found COMPOSITIONS AND METHODS RELATING TO THE PRODUCTION OF ERYTHROPOIETIN
US7459152B2 (en) * 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
CA2520891C (en) 2003-05-09 2014-07-08 Crucell Holland B.V. Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
WO2004101600A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel poly(ethylene glycol) modified compounds and uses thereof
PL1629007T3 (pl) * 2003-05-12 2009-09-30 Affymax Inc Nowe peptydy wiążące się z receptorem erytropoetyny
PL1625156T3 (pl) * 2003-05-12 2013-03-29 Affymax Inc Peptydy wiążące się do receptora erytropoetyny
EP1628686A2 (en) * 2003-05-12 2006-03-01 Affymax, Inc. Spacer moiety for poly (ethylene glycol)-modified peptides
AU2004240782B2 (en) * 2003-05-23 2011-04-21 Crucell Holland B.V. Production of recombinant IGM in per.C6 cells
CA2528988C (en) 2003-06-10 2012-05-01 Lg Life Sciences Ltd. Stable, aqueous solution of human erythropoietin, not containing serum albumin
EP2216415B2 (en) * 2003-08-01 2017-01-04 Life Technologies Corporation Methods for preparing short RNA molecules
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US7645733B2 (en) 2003-09-29 2010-01-12 The Kenneth S. Warren Institute, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
DE502004011252D1 (de) 2003-12-30 2010-07-15 Augustinus Bader Verwendung des erythropoietins zur regeneration von lebergewebe
EP1711159B1 (en) 2003-12-30 2013-03-20 Durect Corporation Solid implants containing a block copolymer for controlled release of a gnrh compound
CA2551916C (en) * 2003-12-31 2014-04-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Fc-erythropoietin fusion protein with improved pharmacokinetics
DE102004004509B4 (de) 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US7846898B2 (en) * 2004-02-13 2010-12-07 Stem Cell Therapeutics Corp. Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis
US7255288B2 (en) * 2004-03-08 2007-08-14 Wan Shan Chan Aroma therapy for fountain
JP5396019B2 (ja) 2004-03-11 2014-01-22 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート
CN1946742A (zh) 2004-03-11 2007-04-11 弗雷泽纽斯卡比德国有限公司 通过还原氨基化制备的羟烷基淀粉和蛋白质的偶联物
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US20090005292A1 (en) * 2004-11-11 2009-01-01 Affymax, Inc. Novel Peptides that Bind to the Erythropoietin Receptor
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006061853A2 (en) * 2004-12-10 2006-06-15 Serum Institute Of India Limited Novel erythropoietic compounds and a process for producing erythropoietic compounds
WO2006089228A2 (en) * 2005-02-16 2006-08-24 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
ES2453981T3 (es) 2005-08-31 2014-04-09 University Of Tennessee Research Foundation Tratamiento de síntomas de enfermedad renal con moduladores selectivos de receptor de andrógenos (SARM)
EP1762250A1 (en) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
AU2006297041A1 (en) 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
US9388382B2 (en) * 2005-10-05 2016-07-12 The Board Of Trustees Of The University Of Illinois Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
WO2008048671A1 (en) * 2006-10-18 2008-04-24 University Of Illinois Embryonic-like stem cells derived from adult human peripheral blood and methods of use
EP1966237A2 (en) * 2005-11-24 2008-09-10 Laboratoires Serono SA Erythropoietin polypeptides and uses thereof
US7972810B2 (en) † 2005-12-08 2011-07-05 Amgen Inc. Production of glycoproteins using manganese
WO2007077217A2 (en) 2006-01-04 2007-07-12 Baxter International Inc. Oligopeptide-free cell culture media
DE102006004008A1 (de) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
EP2004212A4 (en) * 2006-03-17 2010-07-14 Stem Cell Therapeutics Corp CONTINUOUS DOSING SCHEMES FOR NEURAL STEM CELL PROLIFERATING AGENTS AND NEURAL STEM CELL DIFFERENTIATING AGENTS
EP1997505A4 (en) 2006-03-22 2013-02-13 Chugai Pharmaceutical Co Ltd PREPARATION OF ERYTHROPOIETIN SOLUTION
CN101062407A (zh) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 促红细胞生成素在预防或治疗视网膜损伤中的用途
KR101460693B1 (ko) 2006-07-12 2014-11-17 유니버시티 오브 테네시 리서치 파운데이션 치환된 아실아닐리드 및 그의 사용 방법
DK2054074T3 (da) 2006-08-04 2014-11-03 Prolong Pharmaceuticals Llc Modificeret erythropoietin
JPWO2008023725A1 (ja) 2006-08-22 2010-01-14 中外製薬株式会社 末梢神経障害の予防および／または治療剤
CN101528214B (zh) 2006-08-24 2013-06-05 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
KR101470472B1 (ko) * 2006-09-14 2014-12-09 메드제닉스 메디칼 이스라엘 리미티드 장기 지속형 약물 제형
KR101248252B1 (ko) 2006-11-28 2013-03-27 한올바이오파마주식회사 변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도
EP2089424B1 (en) * 2006-12-06 2015-07-01 JCR PHARMACEUTICALS Co., LTD. Method for production of human erythropoietin
EP2121017A2 (en) * 2006-12-19 2009-11-25 Nokad Method for inhibiting the expression of endogenous erythropoietin (epo)
MX2009008104A (es) * 2007-02-02 2009-08-07 Amgen Inc Hepcidina, antagonistas de hepcidina y metodos de uso.
AR065613A1 (es) 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20100172919A1 (en) 2007-06-15 2010-07-08 Jan Grimm Noveltreatment for neurological disorders
WO2009010107A1 (en) 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
CA2720628A1 (en) 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
EP2205280B1 (en) * 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
ES2962777T3 (es) 2007-11-15 2024-03-21 Amgen Inc Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
US9175078B2 (en) 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
MX2010008632A (es) 2008-02-08 2010-08-30 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
US8653249B2 (en) * 2008-02-27 2014-02-18 Fuso Pharmaceutical Industries, Ltd. Expression vector for mass production of foreign gene-derived protein using animal cell and use thereof
EP2095829A1 (en) 2008-02-27 2009-09-02 LEK Pharmaceuticals D.D. Selenium containing modifying agents and conjugates
JP2011519279A (ja) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
DE102008002209A1 (de) 2008-06-04 2009-12-10 Evonik Degussa Gmbh Verfahren zur Aufreinigung von Erythropoietin
DE102008002210A1 (de) 2008-06-04 2009-12-10 Evonik Degussa Gmbh Verfahren zur fermentativen Herstellung von Erythropoietin
WO2009155481A1 (en) * 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
US20120172299A1 (en) 2008-09-23 2012-07-05 F. Hoffmann-La Roche Ag Purification of erythropoietin
ES2631915T3 (es) 2008-09-26 2017-09-06 Ambrx, Inc. Polipéptidos modificados de eritropoyetina animal y sus usos
CA3019967A1 (en) 2008-11-13 2010-05-20 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation of bmp-6
DE102008054716A1 (de) 2008-12-16 2010-06-17 Evonik Degussa Gmbh Inprozesskontrolle in einem Verfahren zur Herstellung von EPO
EP2385115B1 (en) 2008-12-22 2015-09-09 National University Corporation Hokkaido University Expression vector for producing protein derived from foreign gene in large quantity using animal cells, and use thereof
US20100272816A1 (en) 2009-04-27 2010-10-28 Wolfgang Rudinger Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
MX356669B (es) 2009-05-02 2018-06-08 Genzyme Corp Terapia genica para trastornos neurodegenerativos.
CN102712688B (zh) 2009-09-23 2015-06-24 通益制药有限公司 重组人红细胞生成素(epo)的纯化方法、由此纯化的epo以及包含纯化的epo的药物组合物
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
SG194370A1 (en) 2010-06-07 2013-11-29 Amgen Inc Drug delivery device
WO2011159758A2 (en) 2010-06-15 2011-12-22 Medgenics Medical Israel Ltd. Long lasting drug formulations
EP3305315A1 (en) 2010-09-28 2018-04-11 Aegerion Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
CA2831100C (en) 2011-03-31 2020-02-18 Mark Dominis Holt Vial adapter and system
SI2699293T1 (sl) 2011-04-20 2019-05-31 Amgen Inc. Avtoinjekcijski aparat
EP3045188B1 (en) 2011-10-14 2020-12-23 Amgen Inc. Injector and method of assembly
KR101443257B1 (ko) * 2011-10-18 2014-09-19 주식회사 종근당 낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법
US11707410B2 (en) 2011-10-25 2023-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10350139B2 (en) 2011-10-25 2019-07-16 Corning Incorporated Pharmaceutical glass packaging assuring pharmaceutical sterility
RU2717835C2 (ru) 2012-07-13 2020-03-26 Джи Ти Икс, ИНК. Способ лечения андроген-рецептор(ar)-положительных форм рака молочной железы с использованием селективных модуляторов андрогенных рецепторов (sarm)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
EP2906683B1 (en) 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP3072548B1 (en) 2012-11-21 2019-03-06 Amgen, Inc Drug delivery device
KR20150127582A (ko) 2013-03-14 2015-11-17 샤이어 휴먼 지네틱 테라피즈 인크. 4''-티오 개질된 뉴클레오티드를 갖는 리보핵산 및 관련 방법
EP2968760B1 (en) 2013-03-15 2024-01-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
BR112015022042B1 (pt) 2013-03-15 2023-01-10 Amgen Inc Injetor para injetar um produto terapêutico
WO2014138921A1 (en) 2013-03-15 2014-09-18 Apotex Inc. Enhanced liquid formulation stability of erythropoietin alpha through purification processing
TWI639449B (zh) 2013-03-15 2018-11-01 美商安美基公司 用於注射器之匣盒
LT2976117T (lt) 2013-03-22 2021-02-25 Amgen Inc. Purkštuvas ir surinkimo būdas
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707155B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en) 2013-04-24 2017-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
AU2014310555B2 (en) 2013-08-20 2018-01-18 Lek Pharmaceuticals D.D. Cell culture medium and process for controlling alpha-amidation and/or C-terminal amino acid cleavage of polypeptides
US20150118187A1 (en) 2013-10-24 2015-04-30 Medgenics Medical Israel Ltd. Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof
EP3501575B1 (en) 2013-10-24 2021-12-01 Amgen Inc. Drug delivery system with temperature-sensitive-control
JP7086520B2 (ja) 2013-10-24 2022-06-20 アムジエン・インコーポレーテツド インジェクター及び組み立ての方法
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
SG11201609219QA (en) 2014-05-07 2016-12-29 Amgen Inc Autoinjector with shock reducing elements
EP3148587B1 (en) 2014-05-30 2021-02-24 Pfizer Inc Carbonitrile derivatives as selective androgen receptor modulators
EP3152694B1 (en) 2014-06-03 2024-03-06 Amgen Inc. Systems and methods for remotely processing data collected by a drug delivery device
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
CA2957960C (en) 2014-10-14 2023-08-22 Amgen, Inc. Drug injection device with visual and audible indicators
EP3689394A1 (en) 2014-12-19 2020-08-05 Amgen Inc. Drug delivery device with live button or user interface field
EP3848072A1 (en) 2014-12-19 2021-07-14 Amgen Inc. Drug delivery device with proximity sensor
MX391511B (es) 2015-02-17 2025-03-04 Amgen Inc Dispositivo de administracion de farmacos con sujecion asistida de vacio y/o respuestas.
US11806509B2 (en) 2015-02-27 2023-11-07 Amgen Inc. Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
WO2017068051A1 (en) 2015-10-21 2017-04-27 Lek Pharmaceuticals D.D. Peg-based dendron and process for producing the same
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
ES3039908T3 (en) 2016-03-15 2025-10-27 Amgen Inc Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
EP3455142B1 (en) 2016-05-13 2023-08-09 Amgen Inc. Vial sleeve assembly
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
US20190358411A1 (en) 2017-01-17 2019-11-28 Amgen Inc. Injection devices and related methods of use and assembly
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
JP7064501B2 (ja) 2017-02-17 2022-05-10 アムジエン・インコーポレーテツド 無菌流体流路を備える薬物送達デバイスおよび関連する組立方法
JP2020508803A (ja) 2017-03-06 2020-03-26 アムジエン・インコーポレーテツド 作動防止特徴部を備える薬物送達デバイス
AU2018230546B2 (en) 2017-03-07 2024-03-21 Amgen Inc. Needle insertion by overpressure
WO2018165499A1 (en) 2017-03-09 2018-09-13 Amgen Inc. Insertion mechanism for drug delivery device
EP3570871B1 (en) 2017-03-20 2020-11-18 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
CN114588404B (zh) 2017-03-28 2024-07-09 美国安进公司 柱塞杆和注射器组件系统以及方法
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
CA3061982A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
KR102268647B1 (ko) 2017-06-12 2021-06-23 한국코러스 주식회사 안정성이 향상된 에리스로포이에틴 조성물 및 이의 제조방법
CA3063920A1 (en) 2017-06-22 2018-12-27 Amgen Inc. Device activation impact/shock reduction
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM
IL271173B2 (en) 2017-07-21 2024-04-01 Amgen Inc Gas permeable sealing member for drug container and methods of assembly
JP7242562B2 (ja) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
EP3691716B1 (en) 2017-10-06 2023-11-29 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
EP3703778A1 (en) 2017-11-03 2020-09-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
EP3707075A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Fill-finish assemblies and related methods
AU2018358749B2 (en) 2017-11-06 2024-02-29 Amgen Inc. Drug delivery device with placement and flow sensing
JP7247174B2 (ja) 2017-11-10 2023-03-28 アムジエン・インコーポレーテツド 薬物送達デバイスのプランジャ
MA50904A (fr) 2017-11-16 2020-09-23 Amgen Inc Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament
AU2018368338B2 (en) 2017-11-16 2024-07-25 Amgen Inc. Autoinjector with stall and end point detection
JP7264353B2 (ja) 2018-05-24 2023-04-25 国立大学法人北海道大学 新規ベクターおよびその利用
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
CA3103682A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
MA53379A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
EP3829692A1 (en) 2018-07-31 2021-06-09 Amgen Inc. Fluid path assembly for a drug delivery device
EP3856284A1 (en) 2018-09-24 2021-08-04 Amgen Inc. Interventional dosing systems and methods
US12042642B2 (en) 2018-09-28 2024-07-23 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
MX2021003492A (es) 2018-10-02 2021-06-18 Amgen Inc Sistemas de inyeccion para la administracion de farmacos con transmision de fuerza interna.
JP7547325B2 (ja) 2018-10-05 2024-09-09 アムジエン・インコーポレーテツド 投薬量インジケータを有する薬物送達デバイス
WO2020081480A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
SG11202103800RA (en) 2018-10-15 2021-05-28 Amgen Inc Drug delivery device having damping mechanism
EP3873563A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US20220160972A1 (en) 2019-04-24 2022-05-26 Amgen Inc. Syringe sterilization verification assemblies and methods
WO2021041067A2 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
WO2022246055A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
WO2023209074A1 (en) 2022-04-28 2023-11-02 Institut National de la Santé et de la Recherche Médicale Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
CN120380163A (zh) 2022-11-02 2025-07-25 豪夫迈·罗氏有限公司 用于生产糖蛋白组合物的方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3033753A (en) * 1959-08-31 1962-05-08 Wilfrid F White Erythropoietic factor purification
US3865801A (en) * 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
US4468464A (en) * 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4264731A (en) * 1977-05-27 1981-04-28 The Regents Of The University Of California DNA Joining method
JPS5455790A (en) * 1977-10-05 1979-05-04 Tomoyuki Tajima Production of erythropoetin
US4254095A (en) * 1978-04-27 1981-03-03 Research Corporation Radioimmunoassay for erythropoietin
US4411994A (en) * 1978-06-08 1983-10-25 The President And Fellows Of Harvard College Protein synthesis
US4273875A (en) * 1979-03-05 1981-06-16 The Upjohn Company Plasmid and process of isolating same
US4293652A (en) * 1979-05-25 1981-10-06 Cetus Corporation Method for synthesizing DNA sequentially
JPS5653696A (en) * 1979-10-09 1981-05-13 Ajinomoto Co Inc Isolation of erythropoietin by adsorption
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4568448A (en) * 1980-11-26 1986-02-04 Mobil Oil Corporation Hydrodesulfurization process employing poison-resistant catalyst
US4358535A (en) * 1980-12-08 1982-11-09 Board Of Regents Of The University Of Washington Specific DNA probes in diagnostic microbiology
US4503151A (en) * 1980-12-10 1985-03-05 Research Corporation Recombinant cDNA construction method and hybrid nucleotides useful in cloning
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
JPS57149228A (en) * 1981-03-11 1982-09-14 Ajinomoto Co Inc Novel erythropoietin and its preparation
CA1190838A (en) * 1981-07-17 1985-07-23 Cavit Akin Homogeneous nucleic acid hybridization diagnostics by non-radiative energy transfer
CA1180647A (en) * 1981-07-17 1985-01-08 Cavit Akin Light-emitting polynucleotide hybridization diagnostic method
US4442205A (en) * 1981-09-22 1984-04-10 The United States Of America As Represented By The Department Of Health And Human Services Simian virus recombinant that directs the synthesis of hepatitis B surface antigen
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
IL68561A (en) * 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4558005A (en) * 1982-09-13 1985-12-10 University Patents, Inc. Monoclonal anti-erythropoietin
US4713339A (en) * 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) * 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
IE56716B1 (en) * 1983-01-19 1991-11-20 Genentech Inc Method for producing human tpa and expression vectors therefor
US4558006A (en) * 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
JPH0686480B2 (ja) * 1983-02-21 1994-11-02 雪印乳業株式会社 エリスロポエチン製造用モノクローナル抗体
JPS60501140A (ja) * 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
US4710473A (en) * 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
JPS6043395A (ja) * 1983-08-19 1985-03-07 Sumitomo Chem Co Ltd エリスロポエチンの製造法
US4695542A (en) * 1983-10-04 1987-09-22 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
JPH07106156B2 (ja) * 1983-10-28 1995-11-15 ジェネティックス、インスティチュ−ト ファクタ−▲ｖｉｉｉ▼および関連生産物の製造
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
IT1185503B (it) * 1984-01-11 1987-11-12 Univ New York Cloni di odna di eritropietina umana
US4568488A (en) * 1984-01-11 1986-02-04 Lee Huang Sylvia Reverse immunoaffinity chromatography purification method
GB8407498D0 (en) * 1984-03-22 1984-05-02 Biogen Nv High copy number expression vectors
JPS60215632A (ja) * 1984-04-12 1985-10-29 Japan Found Cancer エリスロポエチンの製造法
IL77081A (en) * 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4667016A (en) * 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
JP3344027B2 (ja) * 1993-09-21 2002-11-11 ソニー株式会社 ドライエッチング方法

Also Published As

Publication number Publication date
IL73785A0 (en) 1985-03-31
MX9203598A (es) 1992-09-01
JPH03259098A (ja) 1991-11-19
EP0148605B1 (en) 1990-07-25
JP2708099B2 (ja) 1998-02-04
AU2042192A (en) 1992-10-08
JP3375614B2 (ja) 2003-02-10
AU600650B2 (en) 1990-08-23
NL930128I1 (nl) 1993-11-01
JP2002045191A (ja) 2002-02-12
AU657555B2 (en) 1995-03-16
JPH0693000A (ja) 1994-04-05
JP2655750B2 (ja) 1997-09-24
US5618698A (en) 1997-04-08
AU3612597A (en) 1997-12-18
HK20093A (en) 1993-03-19
WO1985002610A1 (en) 1985-06-20
EP0148605B2 (en) 1998-12-23
AU1007495A (en) 1995-04-06
JPH0776239B2 (ja) 1995-08-16
CY1643A (en) 1993-05-14
AU5272293A (en) 1994-03-24
JP3276933B2 (ja) 2002-04-22
US5441868A (en) 1995-08-15
AU5750490A (en) 1990-10-04
AU3746785A (en) 1985-06-26
EP0148605A2 (en) 1985-07-17
JPH03198792A (ja) 1991-08-29
JP3017962B2 (ja) 2000-03-13
JPH08269096A (ja) 1996-10-15
CA1339047C (en) 1997-05-27
JPH11253188A (ja) 1999-09-21
EP0148605A3 (en) 1987-06-03
JPH0655136B2 (ja) 1994-07-27
ES538519A0 (es) 1988-05-01
JPH0435159B2 (enExample) 1992-06-10
DE3482828D1 (de) 1990-08-30
SG92891G (en) 1992-02-14
IL73785A (en) 1992-11-15
JP2957974B2 (ja) 1999-10-06
JPH1072366A (ja) 1998-03-17
US5756349A (en) 1998-05-26
JPS6455190A (en) 1989-03-02
JPH1095799A (ja) 1998-04-14
NZ210501A (en) 1991-08-27

Similar Documents

Publication Publication Date Title
ES8802329A1 (es) Un procedimiento para preparar un polipetido que tiene en parte o en su totalidad la conformacion estructural primaria de la critropoyetina de origen natural.
AU6334686A (en) Production of pluripotent granulocyte colony-stimulating factor
EP0447483A4 (en) Dopamine receptors and genes
IL88472A0 (en) Mammalian interleukin-1 receptor protein dnas and expression vectors encoding them,processes for producing them and pharmaceutical compositions containing them
CA2338820A1 (en) Overexpression of desired proteins in eukaryotic cells mediated by cyclin d1 overexpression
IL88151A (en) Interleukin-7 protein, dna sequences encoding it, its preparation and compositions containing it
IL91705A0 (en) Interleukin-4 receptors,dna and expression vectors encoding them and process for producing the receptors
AU2670688A (en) Co-expression in eukaryotic cells
HUT60769A (en) Process for producing polypeptides
EP0275204A3 (en) Production of fibroblast growth factor
JO1694B1 (en) New chemical products
FI852377L (fi) Menetelmä erytropoietiinin valmistamiseksi ja siinä käytettyjä DNA-sekvenssejä
CA2033069A1 (en) Saf polypeptide, gene, promoter and use for expression in streptomyces
AU2209988A (en) Method for increasing the expression of polypeptides in recombinant cell culture
DK365185A (da) Fremstilling af erythropoietin.
DE69941789D1 (de) In vivo-verfahren zur herstellung von proteinen, die nicht-konventionelle aminosäuren enthalten
Cannon et al. Spectinomycin-resistant mutants of Bacillus subtilis with altered sporulation properties
JPS58501406A (ja) エシエリヒア・コリ−における蛋白合成発現の高揚
Souza Methods of treating bacterial inflammation and granulocytopoiesis by administering human pluripotent granulocyte colony-stimulating factor
TIMMIS¹ The Cloning of Replication Origins

Legal Events

Date Code Title Description
GD1A Contractual licences

Effective date: 20001110

FD2A Announcement of lapse in spain

Effective date: 20151230